Literature DB >> 10782927

A germline mutation at the extreme 3' end of the APC gene results in a severe desmoid phenotype and is associated with overexpression of beta-catenin in the desmoid tumor.

J Couture1, A Mitri, R Lagace, R Smits, T Berk, H L Bouchard, R Fodde, B Alman, B Bapat.   

Abstract

Desmoid tumors arise sporadically or as part of the extraintestinal manifestations of familial adenomatous polyposis (FAP). In FAP, two distinct clinical presentations of the desmoid phenotype are seen: 1) one or a few desmoid tumors present predominantly in the abdominal wall or the abdomen; 2) a florid proliferation of tumors early in life, mostly near the axial skeleton or extremities. These different phenotypes have been associated with different sites of germline mutations in the adenomatous polyposis coli gene (APC gene). We present a large, French-Canadian kindred with a florid desmoid tumor phenotype caused by a germline mutation at codon 2643-2644 of the APC gene. The phenotype was characterized by the early onset of multiple tumors, arising near the axial skeleton and in proximal extremities. The penetrance of desmoid tumors was near 100% in this kindred. However, the expression of the disease was variable amongst the different affected relatives. Many gene carriers had cutaneous cysts. Polyposis of the colon was rarely observed in the affected individuals and we did not document upper gastro-intestinal polyps. The mutant APC allele did not express a stable truncated protein in vivo. Molecular analysis of the proband's tumor DNA revealed a somatic inactivating mutation of the wild-type allele. Immunohistochemistry on the tumor also demonstrated elevated levels of beta-catenin. The present study demonstrates that this extreme 3' APC mutation is associated with a severely penetrant desmoid phenotype and attenuated polyposis coli. It also suggests the involvement of the beta-catenin pathway in the development of desmoid tumors in FAP. The natural history of the disease is variable between individuals, and surgical interventions have to be timed appropriately due to the frequent recurrences.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10782927     DOI: 10.1034/j.1399-0004.2000.570306.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  12 in total

Review 1.  Current ideas in desmoid tumours.

Authors:  N Julian H Sturt; Susan K Clark
Journal:  Fam Cancer       Date:  2006       Impact factor: 2.375

2.  An association between the 4G polymorphism in the PAI-1 promoter and the development of aggressive fibromatosis (desmoid tumor) in familial adenomatous polyposis patients.

Authors:  Catherine F Li; Robert Y Wei; Frank Baliko; Bharati Bapat; Benjamin A Alman
Journal:  Fam Cancer       Date:  2007       Impact factor: 2.375

3.  A novel frameshift mutation in exon 12 of the adenomatous polyposis coli gene in an Italian family with familial adenomatous polyposis and desmoid tumour.

Authors:  Maria Teresa Vietri; Vietri Maria Teresa; Francesco Selvaggi; Selvaggi Francesco; Maria Laura De Paola; De Paola Maria Laura; Guido Sciaudone; Sciaudone Guido; Ilaria Guadagni; Guadagni Ilaria; Mariarita Parisi; Parisi Mariarita; Gianluca Pellino; Pellino Gianluca; Anna Maria Molinari; Molinari Anna Maria; Michele Cioffi; Cioffi Michele
Journal:  J Mol Genet Med       Date:  2010-05-13

Review 4.  Canine sarcomas as a surrogate for the human disease.

Authors:  Daniel L Gustafson; Dawn L Duval; Daniel P Regan; Douglas H Thamm
Journal:  Pharmacol Ther       Date:  2018-03-09       Impact factor: 12.310

Review 5.  Desmoid tumour in familial adenomatous polyposis. A review of literature.

Authors:  A L Knudsen; S Bülow
Journal:  Fam Cancer       Date:  2001       Impact factor: 2.375

6.  Aggressive mutation in a familial adenomatous polyposis syndrome family: when phenotype guides clinical surveillance.

Authors:  Florencia Neffa; Lucia Garcia; Adriana Della Valle; Florencia Carusso; Carolina Vergara; Daniel Sanchez; Marta Sapone; Noelia Silveyra; Ana Laura Revello; Patricia Esperon
Journal:  J Gastrointest Oncol       Date:  2018-06

7.  A high throughput screen identifies Nefopam as targeting cell proliferation in β-catenin driven neoplastic and reactive fibroproliferative disorders.

Authors:  Raymond Poon; Helen Hong; Xin Wei; James Pan; Benjamin A Alman
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

8.  Role of β-catenin expression in paediatric mesenchymal lesions: a tissue microarray-based immunohistochemical study.

Authors:  A Santoro; G Pannone; M E Errico; D Bifano; G Lastilla; P Bufo; C Loreto; V Donofrio
Journal:  Eur J Histochem       Date:  2012-07-02       Impact factor: 3.188

9.  Extra-abdominal desmoid tumors associated with familial adenomatous polyposis.

Authors:  George T Calvert; Michael J Monument; Randall W Burt; Kevin B Jones; R Lor Randall
Journal:  Sarcoma       Date:  2012-06-03

10.  Gene expression profiling in familial adenomatous polyposis adenomas and desmoid disease.

Authors:  Nikola A Bowden; Amanda Croft; Rodney J Scott
Journal:  Hered Cancer Clin Pract       Date:  2007-06-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.